Pemazyre is approved and reimbursed.

Pemazyre is approved and reimbursed in Belgium as from 1 st July 2022 for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Pemazyre is a kinase inhibitor for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2...